Trial update - Brii Biosciences: BRII-732 as part of an oral QW regimen for HIV treatment and PrEP

Brii Biosciences published a clinical development update in which it announced the discontinuation of BRII-778, a RPV long-acting reformulation, citing the Ph1 PK data presented at IDWeek 2022 to support this decision (12/27).

• • The company also highlighted that development of BRII-732, an ISL prodrug, will continue to explore lower oral doses following the lift of its clinical hold.
  • Brii now intends to explore partnership opportunities to continue development of BRII-732 as part of an oral QW regimen for HIV treatment and PrEP

Additional information to the following link: https://www.biospace.com/article/brii-biosciences-provides-update-on-strategic-clinical-development-progress-december-27-2022/